EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of metabolic reprogramming in pancreatic cancer chemoresistance

Chang Liu, Changfeng Li, Yuanda Liu

Frontiers in Pharmacology · 09.01.2023 · 13

DOI: 10.3389/fphar.2022.1108776 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.01.2023. Verfasst von Chang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, China. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Finance of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is characterized by hidden onset, high malignancy, and early metastasis. Although a few cases meet the surgical indications, chemotherapy remains the primary treatment, and the resulting chemoresistance has become an urgent clinical problem that needs to be solved. In recent years, the importance of metabolic reprogramming as one of the hallmarks of cancers in tumorigenesis has been validated. Metabolic reprogramming involves glucose, lipid, and amino acid metabolism and interacts with oncogenes to affect the expression of key enzymes and signaling pathways, modifying the tumor microenvironment and contributing to the occurrence of drug tolerance. Meanwhile, the mitochondria are hubs of the three major nutrients and energy metabolisms, which are also involved in the development of drug resistance. In this review, we summarized the characteristic changes in metabolism during the progression of pancreatic cancer and their impact on chemoresistance, outlined the role of the mitochondria, and summarized current studies on metabolic inhibitors.

Schlagwörter

Stichwörter der Autor:innen

chemoresistancefatty acid synthesisglutamine metabolismglycolysismetabolic reprogrammingpancreatic cancer

Autor:innen und Institutionen

  • Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, China.

Förderung

  • National Natural Science Foundation of China
  • Department of Finance of Jilin Province

Zitieren

APA

Liu, C., Li, C., & Liu, Y. (2023). The role of metabolic reprogramming in pancreatic cancer chemoresistance. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1108776

Vancouver

Liu C, Li C, Liu Y. The role of metabolic reprogramming in pancreatic cancer chemoresistance. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1108776

BibTeX
@article{Liu2023,
  author = {Liu, Chang and Li, Changfeng and Liu, Yuanda},
  title = {The role of metabolic reprogramming in pancreatic cancer chemoresistance},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fphar.2022.1108776}
}
Kostenlos starten →